The key finding
A 2024 review of impact stories from six international health technology assessment (HTA) agencies demonstrates that publicly funded HTA organizations can effectively influence healthcare decision-making in diverse ways. The agencies—from Canada, Malaysia, Taiwan, the UK, and Wales—were finalists for the 2021 and 2022 David Hailey Award, presented by the International Network of Agencies for Health Technology Assessment (INAHTA). Their stories show that rigorous evidence reviews can shape which medical technologies receive government funding, alter clinical practice, and optimize how health systems allocate resources.
What the study looked like
This paper compiled impact narratives from six HTA agencies that were recognized as finalists in INAHTA’s annual awards program. The agencies included Institut national d’excellence en santé et en services sociaux (Canada), Malaysian Health Technology Assessment Section, Ontario Health (Canada), Center for Drug Evaluation (Taiwan), National Institute for Health and Care Excellence (UK), and Health Technology Wales. Each agency submitted a story describing how their HTA work influenced real-world healthcare decisions. Fellow INAHTA member agencies voted to determine finalists and winners. The paper analyzed these narratives to identify common themes and approaches that contributed to meaningful impact, focusing on how evidence assessment translated into policy changes, reimbursement decisions, or changes in health outcomes.
Why researchers think this happened
The authors suggest that HTA impact occurs when agencies successfully bridge the gap between evidence generation and policy implementation. The varied approaches documented across these agencies demonstrate that there is no single formula for achieving influence. Some agencies worked closely with government decision-makers from the start of an assessment, while others focused on making their findings accessible and timely. The researchers note that HTA agencies function as intermediaries, translating complex scientific evidence into actionable recommendations for policymakers who must decide which treatments and technologies to fund. The diversity of successful approaches reflects different healthcare system structures, policy contexts, and stakeholder relationships across countries. These stories collectively reinforce that adaptability and stakeholder engagement are critical to ensuring HTA findings actually shape decisions rather than sitting on shelves.
How to read this carefully
This paper presents success stories selected through a peer-recognition process rather than a systematic evaluation of HTA effectiveness across all agencies. The narratives are self-reported by agencies celebrating their achievements, which may introduce selection bias toward particularly successful cases. The analysis does not include quantitative measures of impact or compare outcomes against agencies whose work had less influence. Additionally, the paper does not detail specific methodological approaches used in each assessment, making it difficult to identify which technical aspects of HTA work contributed most to impact. The healthcare systems and policy environments in these six countries differ substantially, so strategies that worked well in one context may not transfer directly to others.
What this means for everyday life
If you’ve ever wondered how governments decide which medications or medical devices to cover through public insurance, this paper shows the behind-the-scenes process. HTA agencies are working to ensure that the treatments your healthcare system funds are backed by solid evidence of effectiveness and value. For patients, this means that decisions about which new cancer drugs, surgical procedures, or diagnostic tests become available aren’t made arbitrarily—they’re informed by systematic reviews of clinical evidence. The success stories suggest that when these agencies engage effectively with policymakers and the public, the result can be healthcare spending that focuses on interventions that genuinely improve outcomes. While this doesn’t guarantee every beneficial treatment gets funded immediately, it does indicate that evidence-based processes are actively shaping what’s available in healthcare systems from Ontario to Wales to Malaysia.